RxDoctor Payments Data

Erin Soper, APRN

Family · Lexington, KYNPI 1538632609

Payments from drug & device makers

$1,106in general payments, 2019–2025

Across 24 payments — averaging $46.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$274
  • Bayer$204
  • Inari Medical, Inc.$171
  • Boehringer Ingelheim$120
  • Merz North America, Inc.$95
  • Galderma Laboratories, L.p.$54
  • plus $187 from 6 others

What the payments were for

  • Food & beverage$1,106100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,106 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$44,588
Medicare patients
248
Services billed
1,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin28$37,042
MounjaroTirzepatide20$33,325
EliquisApixaban22$22,532
OzempicSemaglutide11$12,114
DuleraMometasone/Formoterol13$6,378
ArexvyRsvpref3 Antigen/As01e/Pf19$6,023
ShingrixVaricella-Zoster Ge/As01b/Pf18$4,049
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,394
Boostrix TdapDiphth,pertuss(Acell),tet Vac33$2,314
Levothyroxine Sodium198$2,076
Atorvastatin Calcium223$1,770
Omeprazole170$1,666
Memantine Hcl24$1,609
Metoprolol Succinate66$1,460
Albuterol Sulfate HfaAlbuterol Sulfate27$1,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$120$37,04228 claims
Lilly USA, LLCMounjaro$35$33,32520 claims
Novo NordiskOzempic$35$12,11411 claims
AbbVieSynthroid$54$1,23722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →